(S)-ethyl 3-methyl-4-oxobutanoate | 888484-41-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-ethyl 3-methyl-4-oxobutanoate
• 英文别名: ethyl (S)-3-methyl-4-oxobutanoate；ethyl (3S)-3-methyl-4-oxobutanoate
• CAS: 888484-41-1
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: PTVUASUIMPCWSD-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-ethyl 3-methyl-4-oxobutanoate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 溴 、 异丙基氯化镁 、 sodium hexamethyldisilazane 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 苯 为溶剂， 反应 19.08h， 生成 (7S)-9-bromo-7-methyl-1,4-dioxaspiro[4.4]non-8-ene
  参考文献：
  名称：

  Total Synthesis of Lathyranoic Acid A

  摘要：

  The first total synthesis of lathyranoic acid A (1) was accomplished stereoselectively in a linear sequence of 20 steps and an overall yield of 1.4%. This modular synthesis featured a cyclic, stereocontrolled Cu-catalyzed intramolecular cyclopropanation to construct the cis-cyclopropane unit, a Grubbs metathesis to construct the gamma-substituted cyclopentenone moiety, and an anion-mediated conjugate addition.

  DOI：

  10.1021/jo102033h
• 作为产物：
  描述：

  ethyl-3-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-(3S)-butanoate 在 高碘酸 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 14.0h， 以70%的产率得到(S)-ethyl 3-methyl-4-oxobutanoate
  参考文献：
  名称：

  Stereospecificity of Retinol Saturase:  Absolute Configuration, Synthesis, and Biological Evaluation of Dihydroretinoids

  摘要：

  Retinol saturase carries out a stereospecific saturation of the C13-C14 double bond of all-trans-retinol to generate (13R)-all-trans-13,14-dihydroretinol. This compound is found in cells expressing mouse or zebrafish retinol saturase and in the livers of mice fed retinyl palmitate. All-trans-13,14-dihydroretinol is oxidized in vivo to all-trans-13,14-dihydroretinoic acid, a highly selective agonist of the retinoic acid receptor. The naturally occurring (13R)-all-trans-13,14-dihydroretinoic acid is a weaker agonist than the (13S) enantiomer, indicating enantioselective recognition by the ligand-binding pocket of this receptor. Consequently the (13S) enantiomer, acting through the retinoic acid receptor, also inhibits adipose differentiation more potently than the (13R) enantiomer.

  DOI：

  10.1021/ja710487q

文献信息

• Copper-Catalyzed γ-Selective and Stereospecific Allylic Alkylation of Ketene Silyl Acetals
  作者：Dong Li、Hirohisa Ohmiya、Masaya Sawamura

  DOI：10.1021/ja111645q

  日期：2011.4.20

  Copper-catalyzed allylic alkylation of ketene silyl acetals proceeded with excellent γ-E-selectivity. Efficient α-to-γ chirality transfer with anti-selectivity occurred in the reaction of enantioenriched secondary allylic phosphates, affording enantioenriched β-branched γ,δ-unsaturated esters. Excellent functional group compatibility was observed.

  铜催化烯酮甲硅烷基缩醛的烯丙基烷基化以优异的γ-E-选择性进行。在对映体富集的仲烯丙基磷酸酯的反应中发生了具有抗选择性的高效 α 到 γ 手性转移，得到对映体富集的 β-支链 γ,δ-不饱和酯。观察到优异的官能团相容性。
• Stereocontrolled synthesis of ( S )-9- cis - and ( S )-11- cis -13,14-dihydroretinoic acid
  作者：Belén Vaz、Rosana Alvarez、Angel R. de Lera

  DOI：10.1016/j.tet.2016.05.006

  日期：2016.7

  Z,Z,E triene to the desired E,Z,E isomer was required prior to the synthesis of (S)-7 via a Suzuki cross-coupling. The same approach to (S)-9 led to substantial isomerization when the Suzuki cross-coupling was used as the last bond-forming reaction. As alternative, the two bond-forming steps were exchanged and the synthesis of (S)-9 was completed using the Z-selective Julia-Kocienski reaction.

  已经立体选择性地合成了具有S构型的13,14-二氢视黄酸的9-顺式和11-顺式立体异构体，分别是（S）-7和（S）-9。前者最近被表征为类视黄醇X受体（RXR）的第一个内源性天然配体。烯丙基砜和醛的Julia-Kocienski反应用作连接步骤，可提供占目标分子整个侧链的三烯基酯的Z异构体。Z，Z，E三烯高度选择性和单向碘诱导的异构化为所需的E，ž，ê异构体之前（在合成时需要小号） - 7经由铃木交叉偶联。当将Suzuki交叉偶联用作最后一个形成键的反应时，用于（S）-9的相同方法导致大量的异构化。作为替代，交换两个键形成步骤并且使用Z-选择性的Julia-Kocienski反应完成（S）-9的合成。
• [EN] STEREOSELECTIVE SYNTHESIS OF 9-CIS.13,14-DIHYDRORETINOIC ACID AND ITS ETHYL ESTERS<br/>[FR] SYNTHÈSE STÉRÉOSÉLECTIVE D'ACIDE 9-CIS.13,14-DIHYDRORÉTINOÏQUE ET DE SES ESTERS D'ÉTHYLE
  申请人：UNIV OF DEBRECEN

  公开号：WO2016181288A1

  公开（公告）日：2016-11-17

  The retinoid X receptors (RXRs) are ligand-activated transcription factors heterodimerize with a number of nuclear hormone receptors, thereby controlling a variety of physiological processes. The invention relates to novel enantiomer compounds which are derivatives of dihydroretinoic acid, their stereoselective synthesis, to pharmaceutical compositions containing the same and to the use of same in the treatment of diseases.

  视黄醇X受体（RXRs）是配体激活的转录因子，与许多核激素受体异源二聚体化，从而控制各种生理过程。本发明涉及一种新型对映体化合物，它们是二氢视黄酸的衍生物，它们的立体选择性合成，含有这些化合物的药物组合物以及在治疗疾病中使用这些化合物。
• COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES
  申请人：Palczewski Krzysztof

  公开号：US20100135977A1

  公开（公告）日：2010-06-03

  A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.

  一种用于治疗哺乳动物主体代谢性疾病的药物组合物，包括治疗有效量的全反式-13,14-二氢视黄醛、全反式-13,14-二氢视黄醛衍生物或能够调节主体中至少一种全反式-13,14-二氢视黄醛或全反式-13,14-二氢视黄醛衍生物水平的药剂。
• Methods for treating obesity or an obesity related condition
  申请人：Case Western Reserve University

  公开号：US08889660B2

  公开（公告）日：2014-11-18

  In one aspect of the present invention, a pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (R)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In another aspect of the present invention, pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (S)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In a further aspect of the present invention, a method is provided for treating a metabolic disease in a mammalian subject. The method includes administering to the subject a pharmaceutical composition comprising at least one all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.

  在本发明的一个方面中，用于治疗哺乳动物主体代谢性疾病的制药组合物包括治疗有效量的（R）-全反式-13,14-二氢视黄醇和药学上可接受的载体或稀释剂。在本发明的另一个方面中，用于治疗哺乳动物主体代谢性疾病的制药组合物包括治疗有效量的（S）-全反式-13,14-二氢视黄醇和药学上可接受的载体或稀释剂。在本发明的进一步方面中，提供了一种用于治疗哺乳动物主体代谢性疾病的方法。该方法包括向主体注射至少一种全反式-13,14-二氢视黄醇、全反式-13,14-二氢视黄醇衍生物或能够调节主体中至少一种全反式-13,14-二氢视黄醇或全反式-13,14-二氢视黄醇衍生物水平的药物组合物。